Australia secured more than 84 million doses of potential COVID-19 vaccines

Australia secured more than 84 million doses of potential COVID-19 vaccines

AstraZeneca scored another deal

As the pharmaceutical companies are getting close to releasing a viable #COVID-19 vaccine, countries worldwide are starting to secure millions of doses. The latest country to be part of this movement is Australia.

Australia announced that it would receive 3.8 million doses of the vaccine developed by AstraZeneca during the first two months of 2021. Currently, the vaccine is in Phase III of clinical trials in the US, Brazil, South Africa, and the UK. It hasn't revealed significant concerns, but it generated strong immune responses. Under the contract, the Australian government could purchase up to 30 million additional doses.

But the government’s mission doesn’t stop here. It will also purchase doses of the #vaccine developed by the University of Queensland (UQ). Unlike the ones from AstraZeneca, the UQ ones will be available mid-2021. The UQ is undergoing pre-clinical testing on 120 adults, following promising results on animal trials. From the University, the government will buy 51 million doses.

According to people familiar with the matter, vulnerable people and healthcare workers will be the first in line to receive the vaccine. However, things are still a topic of discussion among health officials.

Under the agreements, as mentioned before, the government has the possibility of purchasing additional doses. Also, it can donate or sell the remaining vaccines to other countries or international organizations. From nearly 85 million doses, if both vaccines are proven effective, Australia will have around 30 million doses to spare.

As far as both vaccines are concerned, they could require two doses per patient – an initial dose and a booster. The overall deal for both vaccines is of 1.24 billion.

Following today’s announcement, AstraZeneca stock price is trading 3.50% higher. Australia200 ended the session at +0.33%.

Read more about other pharma companies and their vaccines here!

Sources: investing.com, theguardian.com, yahoo.com


Le informazioni contenute nel presente documento sono redatte da CAPEX.com e non costituiscono né devono essere interpretate come suggerimenti di investimento. Le informazioni di cui al presente documento costituiscono comunicazioni di marketing generali a scopo informativo e, in quanto tali, non sono state preparate nel rispetto dei requisiti di legge che promuovono le ricerche di investimento indipendenti. Inoltre, non sono soggette ad alcuna limitazione sulle transazioni condotte in anticipo rispetto alla divulgazione delle ricerche di investimento in questione.

Gli utenti / lettori non dovrebbero fare affidamento esclusivamente sulle informazioni qui presentate e dovrebbero fare le proprie ricerche / analisi anche leggendo la ricerca reale sottostante. Il contenuto è generico e non tiene conto di circostanze personali individuali, esperienza di investimento o situazione finanziaria attuale.

Pertanto, Key Way Investments Ltd non accetta alcuna responsabilità per eventuali perdite di trader a causa dell'uso e del contenuto delle informazioni presentate nel presente documento. Le performance passate non sono un indicatore affidabile dei risultati futuri.